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Abstract
Human echinococcosis is a zoonotic infection caused by larval forms (metacestodes)
of tapeworms of the genus Echinococcus. Among the recognised species, Echinococcus
granulosus and E. multilocularis are of considerable medical importance, causing cystic
and alveolar echinococcosis (AE and CE), respectively. The factors of immunology,
host-genetic inherits, and Echinococcus genetic-diversity and adaption clearly
influence infectious establishment and disease progression. However, subtle
mechanisms between host and parasite interactions/relationships are still open to
study for answers. Despite the global burden, echinococcosis remains a neglected
zoonosis. The importance of environmental factors influencing the transmission
intensity and distribution of Echinococcus species is increasingly being recognised. The
intervention strategies for this public health threat have integrated host immune-
genetic research, parasite adaptation, and genetic diversity analysis, as well as the
transmission dynamic investigations; the limitations of current control programmes
are clearly presented in this study that hampers the elimination of Echinococcus species
worldwide. Continuous efforts by multidiscipline researches are needed.
Keywords: Echinococcus species, host immunology and genetics, Echinococcus genet‐
ic diversity and adaptation, intervention strategies
1. Introduction
The zoonotic disease of echinococcosis (hydatidosis) is one of the most important parasitic
helminth diseases, with over three million people infected worldwide. The two major species
infecting man are Echinococcus multilocularis that causes alveolar echinococcosis (AE) and
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Echinococcus granulosus that causes cystic echinococcosis (CE). Both CE and AE are life
threatening and are associated with severe morbidity. The global burden of human CE exceeds
one million disability-adjusted life years (DALYs), resulting in a loss of at least US$760 million
per annum. Case series and clinical trials show a mortality rate of 2%–4% for CE, but this
increase is marked with poor treatment and care. CE also impacts upon agriculture as E.
granulosus infects domestic livestock, further adding to economic loss. There are 0.4 million
cases of human AE, and survival analysis has shown that, if untreated or if limited treatment
is provided, mortality exceeds 90%, 10–15 years post-diagnosis. There are approximately
18,000 new cases of AE annually, with a total annual burden of 666,434 DALYs.
2. Transmission of Echinococcus species
All Echinococcus species are transmitted to intermediate hosts via the ingestion of eggs and are
transmitted to definitive hosts by means of eating infected cyst/lesion containing organs. The
life cycle of E. multiclocularis involves carnivorous definitive hosts (foxes and dogs) and
intermediate hosts (predominantly microtine rodents).
For E. granulosus, dogs are the major definitive hosts and sheep and other livestock are typical
intermediate hosts. In Australia, however, the definitive hosts for E. granulosus also include
wild dogs and dingoes, while sheep, kangaroos, and wallabies are common intermediate hosts.
Human echinococcosis occurs through the ingestion of Echinococcus eggs from environments
that have been contaminated by the faeces of infected dogs or foxes. Mostly, following close
contact with infected canines carrying Echinococcus eggs on their fur; by ingestion of egg-
contaminated water or food; or by coprophagic flies serving as mechanical vectors for
transmission. Once inside the body, the eggs release oncospheres in the intestine that then
migrate through the circulatory system to various organs of the host, notably the liver and
lungs. Generally, echinococcosis is associated with poverty, which impacts on sanitation and
hygiene, and access to health services, particularly in livestock-raising communities.
3. Epidemiology in Australia and China
Cosmopolite distribution of E. granulosus in a few of countries is completely free from this
parasite contamination, while E. multilocularis mainly occurs in the northern hemisphere; but
it will be an emerging or re-emerging disease in certain countries as a result of ecological
alternatives in modern life (Figure 1). AE and CE are of considerable public health concern,
particularly in parts of Central and Eastern Europe, and especially Northwest China. While
the annual incidence of AE may appear low in many endemic areas (0.03–1.2 per 100,000
inhabitants), it is estimated that many cases are undiagnosed. Human CE is endemic in many
pastoral communities. The mortality rate from CE is lower than that from AE (about 2%–4%),
but increases considerably if medical treatment is unavailable or inadequate.
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Figure 1. The distribution of Echinococcus spp. in Eastern parts of world (Asian and Australia).
3.1. In Australia
E. granulosus occurs in Australia and is prevalent in wildlife. The true extent of human CE in
Australia is not accurately known. It is estimated that 80–100 new cases of CE are diagnosed
annually; however, CE is not a notifiable disease in Australia and has notoriously been under-
reported so the true prevalence of CE is likely to be considerably higher than described. Of
few data that are available for rural Australian communities, it is apparent that some have an
infection index as high as 23.5/100,000. Other data from Western Australia have shown that
the incidence in Aboriginal people was 12.2 times higher than in the equivalent non-Aboriginal
rural population.
3.2. In China
There are approximately 1.3 million people with echinococcosis in China, where the disease
burden is greater than that of any other country. Of the 33 provinces, autonomous regions,
and municipalities in China, at least 20 are considered to be endemic for E. granulosus and at
least five for E. multilocularis. The provinces and autonomous regions with the highest risk of
echinococcosis include Xinjiang, Qinghai, Sichuan, Gansu, and Ningxia Hui Autonomous
Region (NHAR). These provinces/regions are co-endemic for both human CE and AE, with
common cases of co-infections. In addition, significant numbers of CE cases occur in Tibet,
Shaanxi, as well as Inner Mongolia, Heilongjiang Province. There are now 66 million people
at risk of infection.
4. Pathogenesis of human echinococcosis
The initial phase of a primary infection is always asymptomatic for both AE and CE in humans
and may remain so for a matter of months up to many (typically more than 10) years.
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The metacestodes of E. multilocularis develop almost exclusively in the liver as a tumour-like,
infiltrative growth. The rapidly growing cysts can grow up to 20 cm or more in diameter, often
with a central necrotic cavity. A primary infection of E. multilocularis outside of the liver is rare,
but the spread of parasitic larvae from the primary site in the liver to other organs by metastatic
infiltration is not uncommon. AE is typically identified following the investigation of symp‐
toms such as fatigue and weight loss, hepatomegaly and abnormal US, or through routine
laboratory examination.
In CE, E. granulosus metacestodes may develop in almost any organ. For the majority of
patients, however, a single-organ infection site is generally observed with a solitary cyst
localized to the liver or to the lungs. Ultrasound surveys have shown that, while some cysts
may grow up to 50 mm per year, others may persist without change for many years. Liver
cysts also appear to grow at a lower rate than lung cysts. Most CE cases remain asymptomatic
until the cyst compresses or ruptures into neighbouring structures and organs by which time
the disease is already advanced.
5. Disease diagnosis and severity
Patients with AE and CE are diagnosed based on clinical parameters including assessment of
hepatomegaly, jaundice and upper abdominal complaints, as well as by imaging techniques
such as ultrasound (US), computed tomography (CT) scans and magnetic resonance imaging
(MR). ELISA-based detection of serum Echinococcus specific-antibodies and histological
examination are also used to confirm diagnosis.
To assess the degree of hepatic involvement of the parasite mass, AE patients are classified
according to PNM (P: hepatic localization of parasite; N: extrahepatic involvement of neigh‐
bouring organs; M: absence or presence of distant metastases) and staged as P1, P2, P3, or P4
as recommended by WHO guidelines and the European Network for concerted surveillance
of alveolar echinococcosis classification. For CE patients, classification of disease is based on
liver lesion type (CE1, CE2, CE3, CE4 and CE5) at initial diagnosis, as proposed by the WHO
Informal Group on Echinococcosis.
6. Susceptibility of human echinococcosis
Despite its public health significance, the susceptibility of human echinococcosis is poorly
understood. The general factors that may render an individual more susceptible include
malnutrition, co-infection, and immuno-suppression caused by other diseases or through the
use of immuno-suppressive drugs. Several reports of children with cystic echinococcosis were
predominantly located in the lungs. The reason for lung hydatidosis in children may be
explained by either the weaker immune capability in their respiratory system or the faster cyst
growth rate (or both) in young ages than that in adults. Pregnancy has also been thought to
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increase risk of infection or aggravate the disease due to the impaired cellular immunity
frequently observed in pregnant women.
6.1. Host immunology
Immuno-suppression is frequently observed in patients with severe AE or CE. High levels of
circulating Echinococcus antigens can contribute to immune-suppression through polyclonal
over-stimulation. The chronicity of Echinococcus infection results from persistent antigenic
stimulation, polarization of T cell-subset populations and humoral immune responses. Whilst
increased Th1 cell activity has been associated with degeneration of CE and AE lesions and
successful chemotherapy, high Th2 cell activity is typically associated with active disease and
a poor response to chemotherapy. In animals, CE induces local immune-suppression associ‐
ated with increased IL-10 and TGFβ production. Similarly, in humans, IL-10 production plays
a key role in the immune response against E. multilocularis. Other studies show, however, a
clear immunopathology-associated Th2 polarization in patients with progressive disease
related to increased levels of IL-4 and IL-13. Th1/Th2 cytokines have shown association with
susceptibility or resistance to both Em and Eg infection in in vitro studies. Immunological
markers have proved useful for monitoring the natural course of echinococcosis. High
IgG4/IgE levels are associated with active disease whereas IgG1, IgG2 and IgG3 responses
occur when cysts became infiltrated and are destroyed by the host. This highlights the
importance of measuring IgG subclasses individually for a more sensitive index of disease
activity than total IgG levels. Measurement of both cytokine and antibody levels can provide
a more sensitive diagnostic tool for studying the immunological mechanisms involved in
echinococcosis.
6.2. Host genetics
Despite the high morbidity and mortality associated with echinococcosis, relatively few
studies to date have investigated the genetics underlying human susceptibility to the disease.
The case-control studies of candidate genes that have been previously undertaken have
identified a number of associations with susceptibility to human echinococcosis in the HLA
region for both AE and CE. Of these, however, many have not been replicated, likely reflecting
the complexities and diversities of host susceptibility in different ethnic populations, different
environmental conditions, and exposure to different Echinococcus genotypes or strains. The
majority of candidate gene studies have used small cohorts. Only two genes outside of the
HLA loci have been investigated in terms of AE and CE susceptibility. These genes, TAP1 and
TAP2, belong to the MDR/TAP subfamily and have been previously implicated in autoimmune
diseases such as ankylosing spondylitis, type 1 diabetes, and coeliac disease. As with other
complex diseases, it is anticipated that host genetic influences on echinococcosis susceptibility
are likely to comprise multiple additive loci. Indeed, a recent study has demonstrated that
multiple loci exist that contribute to the susceptibility to echinococcosis in mice. This has been
supported by recent evidence that implicated a large number of differentially expressed genes
in murine AE. However, the relevant genes that determine susceptibility to human echino‐
coccosis and the clinical outcome from this severe disease remain largely unknown. It is clear
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that any gene variations that interfere with these interactions may alter the etiopathogenesis
of disease. Given the highly diverse allelic variation within the MHC region observed between
different geographic populations and racial groups, it is plausible that the race and origin of
an individual can greatly affect their phenotype and the subsequent outcome of infection.
7. Echinococcus adaptation/genetics
Echinococcus species have developed their signalling systems for the microenvironment,
encompassing the host insulin acting as a stimulant for larval E. multilocularis development
and revealed an important factor in the pathology of alveolar echinococcosis predominantly
in the host liver.
The extensive genetic variation of E. granulises comprises a number of strains (G1–G10) that
differ in biological features of intermediate host specificity, with diverse viscera involvements,
anitgenicity, transmission dynamics, and infectivity to humans. An abundant AgB in HCF is
involved in the evasion of the immune response of the host due to its ability to inhibit elastase
activity and neutrophils recruitment and to elicit an immunopathology-associated Th2 cell
response. The significantly different expression levels of 14-3-3 proteins in larval E.multilocu‐
laris and E.granulosus provide different growth behaviours of AE and CE in the intermediate
hosts, respectively.
8. Public health threat
To date, over five species are recognized in the genus and four species are already revealed to
be involved in human diseases. The most common forms are E. granulosis and E. multilocula‐
ris responsible for CE and AE, respectively. Two other forms, namely E. oligarthrus and E.
vogeli cause polycystic echinococcosis; two new species, E. felidis and E. shiquicus may also
contribute to human infection, though little is known.
However, human behavioural changes with economic, technological development, and the
spatial expansion of agriculture promoted encroachment into wildlife habits, driven by
increasing human population, leading to ecosystem changes and bringing human, domestic
animals into closer proximity to wildlife. Many recently emerged zoonoses originated in
wildlife have been reported.
9. Intervention strategies
9.1. Immunological/genetic research
Many studies of echinococcosis have provided significant information on risk factors of
infection, as well as on socio-economic influences and ecological determinants of parasite
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transmission. The new immunological/genetic research components for new therapeutic
targets, in combination with standard imaging techniques, will enable rapid and efficient
evaluation of echinococcosis patients. This will not only greatly assist in monitoring disease
progression and treatment efficacy, but also in the development and deployment of new
control strategies and disease surveillance fundamental to reducing morbidity caused by long-
term chronic infection and at a low cost to the health care systems of areas where echinococcosis
is endemic. Further, the genetic study aims that identification of the genes involved in disease
susceptibility can provide valuable insight into the protective and pathogenic mechanisms
involved in the different clinical outcomes of echinococcosis. Understanding these processes
can provide novel therapeutic targets that are essential for the long-term control of the disease
worldwide. A significant, but essential challenge will be to develop strategies for translating
knowledge of novel susceptibility genes into improved patient outcomes from both AE and
CE. Given the considerable inter-individual variation observed in susceptibility to the different
clinical phenotypes and their associated clinical outcomes, it is anticipated that subtle manip‐
ulation of the host immune response will translate into clinical benefits. Genomics offers a
powerful approach to dissect the relevant pathways and may offer novel therapeutic targets
for new drugs against both AE and CE, which are urgently needed as the current albendazole
treatment is far from satisfactory. Definition of the molecules and pathways that are important
in individual patients may eventually lead to a personalised approach to care, with therapy
tailored on the basis of an individual’s genetic background.
9.2. Animal host intervention
Various methods for animal host interventions have been employed in echinococcosis endemic
regions, for example, the culling of dogs/foxes for CE/AE, culling of rodents for AE, and the
anthelminthic treatment (with praziquantel (PZQ)) of dog/foxes for CE/AE. Vaccine develop‐
ment has been ongoing and whilst a vaccine targeting the definitive dog/fox hosts could be a
“magic bullet”, all current candidates have low efficacy. A highly efficacious sheep vaccine for
E. granulosus (Eg95) is currently under investigation but the evidence base, though growing,
is not yet established for its incorporation into control programmes to date.
9.3. Comprehensive intervention and limitation
The use of geographic information system (GIS) have become more common as a tool for public
health investigations due to the increase in number and quality of satellites used for terrestrial
observation. These systems integrate the use of geographic positions sensors (GPS) tool for
infectious disease studies, including Echinococcus. Spatial analysis provides an improvement
in epidemiological analysis and prediction of future events. Using remote sensors for moni‐
toring Echinococcus transmission, particularly E. multilocularis, have produced information that
has showed much importance in designing a control programme. Apart from the detection of
animal host assembling linking transmission dynamics due to prey-predatory relations, in
terms of geological and ecological environments, prediction mapping provides geographical
identification of Echinococcus spp. risk areas, allowing for the allocation of resources in
reasonable ways/location. Linking with a mathematical model has been done in many other
parasitic disease controls. It is believed to be also useful for the determination of the optimal
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strategies for control and/or elimination of echinococcosis in specific locations. The optimal
intervention strategies can be translated into policy and practice reducing the burden of this
disease, leading to improved direct health outcomes. Modelling can also be used for future
economic assessments of interventions that reduce the financial impact of the disease.
To date, only five islands (Iceland, New Zealand, Tasmania, Falkland Islands, and Cyprus)
have been able to successfully control echinococcosis. Control programmes were predomi‐
nantly based on health education and control or elimination of home slaughter of sheep, with
behaviour change, is central to their success.
Despite the range of intervention strategies, control in endemic regions of the world (especially
the poor rural areas) has proved difficult, as demonstrated by the increasing number of cases
over the last decade. This failure to effectively control echinococcosis can be attributed to a
number of causes: 1) culling of animals has ethical challenges (e.g., use of rodenticides in
NHAR resulted in the poisoning of domestic dogs); 2) PZQ is effective in killing adult E.
granulosus and E multilocularis in definitive hosts, but it does not prevent reinfection in the
definitive hosts; 3) existing health promotion materials are passive and may not be sufficiently
engaging to bring about behaviour change at the population level; and 4) the lack of significant
governmental support for control programmes.
10. Conclusion
Hydatid disease is a major cause of morbidity and mortality in many parts of the world.
Although immunological research has provided important insight into the mechanisms of
immunity in CE and AE, the genetic variants within the host-participating genes may be too
subtle or too few to cause much effect on individual risk. The genotypic variation of Echino‐
coccus species reflects phenotypic differences with important consequences in terms of
increased host infectivity by local Echinococcus strains. Such adaptations may also result in
different sensitivity to drugs or increased virulence for hosts that will impede controls efforts
and even affect vaccination strategies against Echinococcus. The environmental factors have
been correlated with transmission to humans through changes in animal population, dynamics
spatial overlap of competent hosts, and the creation of improved conditions for egg survival.
Therefore, echinococcosis is a complex zoonosis with sparse evidence on the effectiveness of
control strategies in diverse settings despite many efforts worldwide for decades. Identifying
the environmental determinants of the transmission risk to humans will be vital for the design
of accurate predictive models to guide preventative public health action against echinococco‐
sis. Mathematic modelling is a useful tool for simulating control packages under locally specific
transmission conditions to inform optimal timing and frequency of phased interventions for
cost-effective control of echinococcosis.
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